Search

Heron Therapeutics Inc

Open

BrancheGesundheitswesen

0.3 -3.23

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

0.3

Max

0.32

Schlüsselkennzahlen

By Trading Economics

Einkommen

2.6M

-5.5M

Verkäufe

3M

38M

EPS

-0.03

Gewinnspanne

-14.573

Angestellte

128

EBITDA

2.1M

-5.5M

Dividenden

By Acuity

Nächstes Ergebnis

3. Nov. 2026

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

-36M

61M

Vorheriger Eröffnungskurs

3.53

Vorheriger Schlusskurs

0.3

Nachrichtenstimmung

By Acuity

11%

89%

18 / 340 Ranking in Healthcare

Heron Therapeutics Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

19. Aug. 2026, 23:56 UTC

News

Wayfair shares rise in after-market hours after Rosenblatt analyst Scott Devitt initiated coverage with a Buy rating and a price target of $125.00.

19. Aug. 2026, 23:56 UTC

News
Social Media

Cogent Communications is facing a class action lawsuit over alleged false statements, contributing to a decline in shares during after-market hours.

19. Aug. 2026, 23:52 UTC

News
Correlated Moves

Cohen & Steers Inc. shares are lower in after-market trading, continuing a trend of five consecutive daily declines. The fund declared a monthly dividend of $0.126 per share.

19. Aug. 2026, 23:51 UTC

News

Biomarin Pharmaceutical Inc shares are lower in after-market hours amid a broader Biotechnology sector decline, despite a recent $275 million acquisition of Alesta Therapeutics.

19. Aug. 2026, 23:51 UTC

News
Social Media

Ultragenyx Pharmaceutical received FDA accelerated approval for its gene therapy GENGLYCOS, leading shares to rise sharply in after-market hours.

19. Aug. 2026, 23:41 UTC

News

Target Corp shares are lower in after-market hours despite stronger-than-expected second-quarter earnings of $4.11 per share and a raised full-year forecast.

19. Aug. 2026, 23:36 UTC

News
Social Media

Rosenblatt analyst Scott Devitt initiated coverage on Amazon.com with a Buy rating. Shares advanced in after-market trading following this positive assessment.

19. Aug. 2026, 23:31 UTC

News

Wendy's Co shares are lower in after-market hours following a management reset and reports of Trian Fund Management exploring a potential buyout.

19. Aug. 2026, 23:26 UTC

News

Constellation Brands announced a $100 million investment over five years to support farmers in Idaho, Montana, and North Dakota. Shares were roughly flat in after-market trading.

19. Aug. 2026, 23:22 UTC

News
Social Media
Correlated Moves

Coinbase Global Inc shares are higher in after-market trading amid bullish social media sentiment and the announcement of direct USDC trading in Brazil.

19. Aug. 2026, 23:21 UTC

Social Media
Correlated Moves
News

Marvell Technology shares rise in after-hours trading following a significant deal with Google, which includes a warrant for 58.97 million shares at $206.58 each.

19. Aug. 2026, 23:21 UTC

Correlated Moves
News

Microstrategy Inc. shares rose in after-market trading, driven by increased bullish options activity and positive remarks on its Bitcoin strategy from executives.

19. Aug. 2026, 23:21 UTC

News

Kratos Defense shares are rising in after-market trading as the U.S. Air Force evaluates alternatives to existing aerial targets, including the BQM-167A.

19. Aug. 2026, 23:21 UTC

Event
Social Media
News

BILL Holdings reported strong Q4 results, with adjusted net income of $94 million. Shares are higher in after-hours trading following the earnings report.

19. Aug. 2026, 23:16 UTC

News

Accuray Inc shares fell in after-market hours following a net loss of $1.94 million and revenue of $100.92 million, missing expectations.

19. Aug. 2026, 23:16 UTC

News
Social Media

Iovance Biotherapeutics shares reached a new 52-week high amid positive melanoma treatment sector sentiment and an anticipated revenue guidance increase.

19. Aug. 2026, 23:16 UTC

News
Social Media

Netflix Inc. is trading higher in after-market hours amid reports of competitive strategies in the streaming industry, including YouTube's incentives for exclusive content.

19. Aug. 2026, 23:11 UTC

News

Carlyle Group invests in Castelion's $1 billion funding round, boosting defense sector engagement. Shares are higher in after-market trading following the announcement.

19. Aug. 2026, 23:11 UTC

News

Northrop Grumman declared a quarterly dividend of $2.47 per share, contributing to shares trading higher in after-market hours.

19. Aug. 2026, 23:11 UTC

Correlated Moves
News

The Australian Dollar is gaining against the Hong Kong Dollar amid rising global bond yields and inflation concerns linked to geopolitical tensions.

19. Aug. 2026, 23:06 UTC

News

Replimune Group shares declined in after-market hours following the grant of equity awards to Chief Commercial Officer Michelle DiNapoli, raising potential dilution concerns.

19. Aug. 2026, 23:06 UTC

News

Ionis Pharmaceuticals is advancing RG-6299 into a pivotal Phase III trial for IgA nephropathy in collaboration with Roche and Chugai. Shares are higher in after-market trading.

19. Aug. 2026, 23:06 UTC

Social Media
News

Hims & Hers Health Inc. shares are lower in after-market trading following a lawsuit from the FTC alleging deceptive practices regarding user privacy and billing.

19. Aug. 2026, 23:06 UTC

News

Chewy Inc shares are lower in after-market trading as cautious sentiment grows ahead of the September earnings call and a Neutral rating from Rosenblatt.

19. Aug. 2026, 23:06 UTC

News
Correlated Moves

Geopolitical tensions and Fed concerns contribute to a decline in the iShares 20+ Year Treasury Bond ETF in after-market trading. The iShares TIPS Bond ETF also moves lower.

19. Aug. 2026, 23:06 UTC

Social Media
News

SPDR Gold Shares trade higher after-market, boosted by social media discussions on its return above the 200-day moving average amid geopolitical tensions and inflation concerns.

19. Aug. 2026, 23:06 UTC

News
Correlated Moves

Geopolitical tensions and inflation concerns support iShares Silver Trust's gains during after-market hours, maintaining a position above its 20-day moving average.

19. Aug. 2026, 23:06 UTC

Correlated Moves
News

Northern Oil and Gas announced a $500 million senior notes offering, contributing to a decline in shares during after-market trading. EOG also fell amid sector dynamics.

19. Aug. 2026, 23:06 UTC

News
Correlated Moves

Twist Bioscience Corp shares are lower in after-market hours following a critical short report from Scorpion Capital questioning the company's AI-driven protein design strategy.

19. Aug. 2026, 23:02 UTC

News

Encore Capital Group appoints Robert Beck to its board, effective immediately. The move has contributed to shares rising in after-market trading.

Peer-Vergleich

Kursveränderung

Heron Therapeutics Inc Prognose

Rating-Konsens

By TipRanks

Neutral

2 ratings

0

Buy

2

Halten

0

Sell

Stimmung

By Acuity

18 / 340 Ranking in Gesundheitswesen

Nachrichtenstimmung

Sehr starke bullische Evidenz

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Überdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Heron Therapeutics Inc

Heron Therapeutics, Inc., a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; and APONVIE, an intravenous formulation of a substance P/neurokinin-1 receptor antagonist indicated for the prevention of postoperative nausea and vomiting in adults. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in Cary, North Carolina.
help-icon Live chat